United Therapeutics Asks FDA to Approve Tyvaso DPI

United Therapeutics Asks FDA to Approve Tyvaso DPI

292271

United Therapeutics Asks FDA to Approve Tyvaso DPI

United Therapeutics has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of Tyvaso DPI, an investigational dry powder inhaled formulation of treprostinil, to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).  PH-ILD is an umbrella term for lung fibrotic-related conditions, including idiopathic pulmonary fibrosis (IPF). With this application, the company also is seeking the approval of Tyvaso DPI for the treatment of pulmonary arterial hypertension…

You must be logged in to read/download the full post.